66% of US doctors now use AI, according to the AMA's February 2025 survey. On paper that reads like a revolution. It isn't. Look at what they use it for and the revolution dissolves.
The top uses are documentation, billing codes, and discharge notes. Paperwork. Only 31% use AI for clinical decisions, the part where a wrong answer changes what happens to a human body. And 82% say liability coverage is critical for adoption. That last number is the whole game, because there is no clear answer to who is liable when the AI is wrong, and "no clear answer" is not a detail. It is the wall.
The headline adoption figure and the clinical adoption figure are measuring two different things. One measures whether a doctor will let a model draft a note. The other measures whether a doctor will let a model influence a diagnosis and stake a license on it. The gap between 66% and 31% is not a capability gap. It is a liability gap, and it is exactly as wide as the unanswered question underneath it.
Move fast and break things does not port to medicine
In software, the operating doctrine is move fast and break things, because breaking things means a rolled-back deploy and an apologetic status page. The cost of an error is bounded, reversible, and usually cheap. That bounded downside is the hidden assumption under every fast-iteration culture in tech.
In medicine the same phrase describes malpractice suits, revoked licenses, and dead patients. Breaking things is unbounded, often irreversible, and paid in outcomes no rollback can undo. A domain where the downside of an error is capped iterates fast. A domain where the downside is catastrophic and personal iterates slowly, and it is correct to iterate slowly. This is not physicians being timid. It is physicians pricing the error accurately.
In tech, breaking things means a rollback. In medicine, it means a lawsuit, a lost license, or a dead patient. The error economics are not comparable.
So the question is not whether the model is good enough. Frontier models already clear many clinical benchmarks. The question is what happens after the model is wrong once, in the real world, on a real patient, and the answer to that question has not been built.
The liability stack is the actual bottleneck
Strip away the noise and the blocker is a single unanswered question. When an AI recommends the wrong diagnosis and a patient is harmed, who gets sued? Three candidates, and today all three are live:
- The physician who trusted the output. If the doctor is liable for following the AI, the AI adds risk rather than removing it, because now the doctor owns both the decision and the machine that shaped it.
- The hospital that deployed the system. If the institution is liable, procurement freezes, because no health system will deploy at scale into open-ended, uninsurable exposure.
- The vendor that built the model. If the maker is liable, the economics of selling clinical AI change completely, and most current business models do not survive the change.
Right now the honest answer is "unclear." And unclear does not scale. Unclear means every deployment is a bespoke negotiation over risk, every general counsel says no by default, and every insurer prices the unknown as uninsurable. You cannot build a market on top of a question no one will answer, and healthcare AI is a market sitting on exactly that question.
This is the same structural failure I described in execution architecture beats model capability: the model responds in seconds, but the chain of accountability behind it does not exist, so nothing ships. Healthcare is that failure in its purest, highest-stakes form, because the error economics are as unforgiving as they get.
Why marketing AI raced ahead and clinical AI didn't
Contrast the two domains and the mechanism is obvious. In marketing, a wrong output is a bad ad, a mistargeted email, a wasted impression. The error is cheap, reversible, and no one gets sued. So marketing absorbed AI at full speed, because the liability stack was trivial and never had to be built.
Clinical AI faces the inverse. The error is expensive, sometimes irreversible, and litigated. The same model capability meets a completely different downside, and the downside, not the capability, sets the adoption rate. This is why AI in healthcare will never move like AI in marketing, no matter how good the models get. The constraint was never the intelligence. It was the consequence.
And notice what this predicts. The domains that adopt AI fastest are not the ones with the best models or the cleverest engineers. They are the ones with the cheapest errors. Adoption speed tracks error cost inversely, across every industry, which is why the frontier of hard AI deployment is always the frontier of hard liability.
Whoever solves accountability wins healthcare AI
If the bottleneck is the liability stack, then the winning move is not a better model. It is the legal and financial architecture that makes the liability question answerable. Concretely, that means some combination of the following, assembled into a product rather than a disclaimer:
- Defined allocation. A contractual, insurable answer to who owns the error, agreed before deployment, not litigated after harm.
- An insurance instrument priced to the actual error rate of the system, so exposure becomes a premium rather than an unknown.
- An audit trail that makes each AI-influenced decision attributable and reviewable, so fault can be located rather than argued.
- A standard of care that specifies how a physician is expected to use the output, converting "trusted the AI" from a liability into a documented, defensible process.
Build that stack and clinical AI moves. Skip it and you have a demo, however good the model looks in the demo. The company that solves accountability first wins healthcare AI. Everyone else is running pilots against a wall they refuse to name.
Key takeaways
- 66% of US doctors use AI, but only 31% for clinical decisions. The gap between those figures is a liability gap, not a capability gap.
- 82% of physicians say liability coverage is critical for adoption, and there is no clear answer to who is liable when AI is wrong.
- Move fast and break things assumes bounded, reversible errors. In medicine the downside is unbounded, irreversible, and litigated.
- When AI harms a patient, the physician, the hospital, and the vendor are all live defendants. "Unclear" liability does not scale.
- Adoption speed tracks error cost inversely: marketing raced ahead because its errors are cheap; clinical AI stalls because its errors are catastrophic.
- The winning move is the legal and financial architecture, not a better model. Whoever solves accountability first wins healthcare AI.
The whole field is chasing the wrong frontier. The race everyone is running is who has the best clinical model. The race that actually decides the market is who builds the liability stack that lets a good model be used. Until someone assembles the legal architecture, better models will keep accumulating in a domain that cannot deploy them, and the same asymmetry will hold that holds everywhere the stakes are real: generation is cheap, but verification cost is the new bottleneck, and in medicine verification is not a code review. It is a life. For the wider map of where accountability, not capability, decides the winners, start with the manifest.
Top comments (0)